Insight

Istvan Petak: Real-world performance analysis of a universal computational reasoning model for precision oncology in lung cancer

Istvan Petak/protechtor.io

Jun 17, 2025, 19:49

Istvan Petak: Real-world performance analysis of a universal computational reasoning model for precision oncology in lung cancer

Istvan Petak, Founder and Chief Scientific Officer at Genomate Health, shared on LinkedIn:

“I am proud and excited to share our latest major publication:

Dirner, A., Kormos, D., Lakatos, D. et al. Real-world performance analysis of a universal computational reasoning model for precision oncology in lung cancer. npj Precis. Onc. 9, 159 (2025).

In this real-world study, metastatic lung cancer patients had a 5-fold higher survival rate after 5 years (33% versus 6%) if treated with targeted therapies supported by a high computational score generated by Genomate’s Digital Drug Assignment (DDA) technology.

Each tumor harbors multiple genetic driver alterations and biomarkers, and most patients may have multiple tests. We have more than two hundred molecularly targeted therapies and many other options to treat cancer patients. DDA-powered clinical decision support helps us identify all patients who can potentially benefit from precision oncology today. DDA evaluates the complete set of molecular diagnostic test results and automatically prioritizes treatment options, considering all identified alterations. It assesses the potential multiple associations between driver alterations, targets, and therapies to ensure that no possible treatment opportunity or potential resistance mechanism is overlooked.

We must enhance consistency and reproducibility in precision oncology to promote equity in accessing the best possible treatments for our patients while alleviating the burden and stress on oncologists, pathologists, and the entire medical team. Computational tools will help us harness the full potential of precision oncology for all our patients. I want to thank the entire Genomate Health team, our partner institutions with which we have collaborated, and all the authors who contributed to this landmark study.”

Title: Real-world performance analysis of a universal computational reasoning model for precision oncology in lung cancer

Authors: Anna Dirner, Dóra Kormos, Dóra Lakatos, Márton Bolyácz, Mária Kocsis-Steinbach, Gábor György Kalmár, Dóra Tihanyi, Ákos Takács, Ákos Boldizsár, Viktor Kardos, Réka Szalkai-Dénes, Barbara Vodicska, Edit Várkondi, Júlia Déri, Gábor Pajkos, Dóra Mathiász, István Vályi-Nagy, Richárd Schwáb, Maud Kamal, Christian Rolfo, Arkadiusz Z. Dudek, Christophe Le Tourneau, Róbert Dóczi, László Urbán, István Peták

Read the Full Article.

Istvan Petak

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

Insight

OncoDaily

Insight

Istvan Petak: Real-world performance analysis of a universal computational reasoning model for precision oncology in lung cancer

“I am proud and excited to share our latest major publication:

Dirner, A., Kormos, D., Lakatos, D. et al. Real-world performance analysis of a universal computational reasoning model for precision oncology in lung cancer. npj Precis. Onc. 9, 159 (2025).

In this real-world study, metastatic lung cancer patients had a 5-fold higher survival rate after 5 years (33% versus 6%) if treated with targeted therapies supported by a high computational score generated by Genomate’s Digital Drug Assignment (DDA) technology.